Life sciences patent owners face a transformed inter partes review environment at the USPTO

The Long Read: Kramer Levin’s Hannah Lee and Irena Royzman look at how changes at the PTAB are playing out for companies in the sector caught up in litigation, while setting out crucial strategic insights that can help both rights holders and petitioners prevail.


Get unlimited access to all IAM content